biostudies-literatureWinkler CCancer Research UKEC | European Regional Development FundClaudia Winkler is supported by an AstraZeneca PostDoc Fellowship funding.Wellcome Trust951-962https://www.ebi.ac.uk/biostudies/studies/S-EPMC7921667biostudies-literatureUnknown124(5)<h4>Background</h4>Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies.<h4>Methods</h4>We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination therapies and mechanistic studies to assess SLFN11 as a potential biomarker for stratification of patients treated with several DDA and/or DDRi in the preclinical and clinical setting.<h4>Results</h4>SLFN11 protein associated with both preclinical and patient treatment response to DDA, but notBritish journal of cancerSLFN11 informs on standard of care and novel treatments in a wide range of cancer models.PMC7921667206194FIS [PI17/01080]Miguel Servet [CP14/00228]Transcan-2 TH4RESPONS (AC15/00063)22897Armenia JLeo ECoker EATobalina LBaird TWinkler CWang ATJones GNO'Connor MJPierce AJSale MJLau APetreus TJaaks PSerra VGarnett MJfalseSLFN11 informs on standard of care and novel treatments in a wide range of cancer models.<h4>Background</h4>Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies.<h4>Methods</h4>We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination therapies and mechanistic studies to assess SLFN11 as a potential biomarker for stratification of patients treated with several DDA and/or DDRi in the preclinical and clinical setting.<h4>Results</h4>SLFN11 protein associated with both preclinical and patient treatment response to DDA, but not2021-01-01T00:00:00Z2021 Mar2026-07-16T01:56:45.094Z2026-07-09T10:36:42.501ZS-EPMC79216673333989410.1038/s41416-020-01199-4